1. Home
  2. FNV vs NTRA Comparison

FNV vs NTRA Comparison

Compare FNV & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franco-Nevada Corporation

FNV

Franco-Nevada Corporation

N/A

Current Price

$264.59

Market Cap

43.6B

ML Signal

N/A

Logo Natera Inc.

NTRA

Natera Inc.

N/A

Current Price

$331.64

Market Cap

45.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FNV
NTRA
Founded
1986
2003
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Medical Specialities
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.6B
45.3B
IPO Year
2009
2015

Fundamental Metrics

Financial Performance
Metric
FNV
NTRA
Price
$264.59
$331.64
Analyst Decision
Buy
Strong Buy
Analyst Count
8
15
Target Price
$248.13
$259.07
AVG Volume (30 Days)
750.2K
1.4M
Earning Date
05-12-2026
05-07-2026
Dividend Yield
0.69%
N/A
EPS Growth
N/A
0.65
EPS
N/A
N/A
Revenue
N/A
$210,939,000.00
Revenue This Year
$55.98
$18.08
Revenue Next Year
$16.81
$19.65
P/E Ratio
$53.29
N/A
Revenue Growth
N/A
N/A
52 Week Low
$181.50
$157.43
52 Week High
$285.67
$333.56

Technical Indicators

Market Signals
Indicator
FNV
NTRA
Relative Strength Index (RSI) 73.75 71.73
Support Level $220.92 $187.64
Resistance Level $269.07 N/A
Average True Range (ATR) 6.83 10.88
MACD 3.07 2.40
Stochastic Oscillator 92.69 96.11

Price Performance

Historical Comparison
FNV
NTRA

About FNV Franco-Nevada Corporation

Franco-Nevada Corp is a precious-metals-focused royalty and investment company. The company owns a diversified portfolio of precious metals and royalty streams, which is actively managed to generate the bulk of its revenue from gold, silver, and platinum. The company does not operate mines, develop projects, or conduct exploration. The company's short-term financial performance is linked to the price of commodities and the amount of production from its portfolio of producing assets. Its long-term performance is affected by the availability of exploration and development capital. The company holds a portfolio of assets, diversified by commodity, revenue type, and stage of a project.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: